安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Ibrutinib Resistance Mechanisms and Treatment Strategies for . . .
BTK is a central contributor to B-cell lymphoma pathogenesis, as it is significantly more active (increased phosphorylation) in B-cell lymphomas than in normal B-cells Additionally, BTK plays a fundamental role in modulating chemokine and integrin signaling (CXCR4), thereby regulating B-cell trafficking and tissue homing [ 7 ]
- Ibrutinib improves diffuse large B-cell lymphoma survival
NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live The new findings come from a new analysis of a previously conducted phase 3 clinical trial called Phoenix
- Imbruvica (Ibrutinib) | Lymphoma News Today
A total of 56 patients with various types of B-cell NHL were enrolled in the study The results showed that Imbruvica was well-tolerated across various types of B-cell NHL The FDA approved Imbruvica in 2013 for the treatment of patients with MCL based on the results of an open-label Phase 2 trial (NCT01236391) During the trial, 111 patients
- IMBRUVICA® (ibrutinib) | Official Patient Website
‡ IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have
- Ibrutinib improves survival for younger people with diffuse . . .
“This new analysis provides a compelling rationale for doctors to consider adding ibrutinib to standard chemotherapy for the initial treatment of younger patients with non-GCB DLBCL,” said Wyndham H Wilson, M D , Ph D , senior investigator in the Lymphoid Malignancies Branch and a co-author of the study DLBCL is the most common type of
- Official Healthcare Professional Website | IMBRUVICA . . .
Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA ® treatment Hypertension: Hypertension occurred in 19% of 1,476 patients with B-cell malignancies who received IMBRUVICA ® in clinical trials Grade 3 or greater hypertension occurred
- Ibrutinib in Patients with Relapsed or Refractory Diffuse . . .
Based on gene profiling, DLBCL can be further classified as activated B-cell-like lymphoma (ABC), germinal center B-cell-like lymphoma (GCB) and primary mediastinal B-cell lymphoma Most patients of DLBCL achieve complete remission (CR) after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), which is
- CLL and SLL Treatment | IMBRUVICA® (ibrutinib)
The most common side effects of IMBRUVICA® in adults with B-cell malignancies (CLL SLL and WM) include low platelet count; diarrhea; tiredness; muscle, bone, and joint pain; low white blood cell count; rash; low red blood cell count (anemia); bruising; and nausea
|
|
|